Breaking News Instant updates and real-time market news.

VRTX

Vertex

$81.66

-4.32 (-5.02%)

, GLPG

Galapagos NV

$64.64

-1.005 (-1.53%)

08:10
10/12/16
10/12
08:10
10/12/16
08:10

Vertex competitor to report data soon, but has long way to go, says RBC Capital

RBC Capital analyst Michael Yee noted that Galapagos NV (GLPG) and partner AbbVie (ABBV) are likely to present new Phase IIa data for GLP-1837 for cystic fibrosis and host an analyst event on October 27, adding that he believes the data will likely be positive and suggest they are "on track" with progress on their triple pill. Yee adds it won't be surprising if Galapagos has positive '1837 "potentiator" data, as this is the easier of the components and only the first piece of a 3-pill drug. Vertex (VRTX) is also hosting an analyst event on Oct. 27 and will probably also give an update on its own "triple," said Yee, who thinks it should stay in the lead with most advanced triple. Yee keeps an Outperform rating on Vertex shares.

VRTX

Vertex

$81.66

-4.32 (-5.02%)

GLPG

Galapagos NV

$64.64

-1.005 (-1.53%)

ABBV

AbbVie

$61.82

-0.92 (-1.47%)

  • 25

    Oct

  • 27

    Oct

  • 28

    Oct

  • 06

    Nov

  • 14

    Dec

VRTX Vertex
$81.66

-4.32 (-5.02%)

10/06/16
JMPS
10/06/16
NO CHANGE
JMPS
Vertex Orkambi checks positive, says JMP Securities
After conducting checks with doctors, JMP Securities analyst Liisa Bayko says that uptake of Vertex's Orkambi drug among 6-11 year old children appears to be "rapid." Bayko expects Orkambi's market share in the age range to reach 70% within six months. She reiterates a $103 price target and Outperform rating on the stock.
09/29/16
JMPS
09/29/16
NO CHANGE
JMPS
Vertex Orkambi approval should drive growth, says JMP Securities
JMP Securities analyst Liisa Bayko says that FDA approval of Vertex's Orkambi in the 6-11 year old population should enable the company to grow in Q4 after a temporary slowdown in Q3. However, the analyst expects Q4 Orkambi sales to come in at $285M, versus the consensus outlook of $295M. She keeps a $103 price target and Outperform rating on the shares.
09/29/16
RBCM
09/29/16
NO CHANGE
RBCM
Vertex should be bought on weakness, says RBC Capital
After Vertex lowered its 2016 Orkambi revenue guidance, RBC Capital analyst Michael Yee says that the news "was not a surprise." The analyst remains upbeat on the company's triple CF treatment, and he recommends buying the stock on weakness. He keeps an Outperform rating on the shares.
09/22/16
PIPR
09/22/16
NO CHANGE
Target $129
PIPR
Overweight
Vertex recent weakness brings buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff views the weakness in shares of Vertex Pharmaceuticals following the company's recent Q3 guidance as a buying opportunity ahead of Orkambi's September 30 PDUFA date in homozygous F508del children. Label expansion for Orkambi should drive cystic fibrosis sales to $478M in Q4, Tenthoff tells investors in a research note. He points out that Vertex will announce data at the North American Cystic Fibrosis Conference from October 27-29. The analyst reiterates an Overweight rating on the shares with a $129 price target.
GLPG Galapagos NV
$64.64

-1.005 (-1.53%)

09/22/16
JANY
09/22/16
NO CHANGE
Target $64
JANY
Buy
Galapagos drug more important to Gilead after trial halt, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Gilead Sciences' (GILD) termination of its combined Phase 2/3 study of GS-5745 in ulcerative colitis implies that Galapagos (GLPG) filgotinib is now potentially more important to Gilead's growth prospects. The analyst, who thinks upcoming data could provide meaningful upside for Galapagos shares even after the stock's 25% move up over the past three weeks, keeps a Buy rating and $64 fair value estimate on the stock.
08/30/16
08/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BofA Merrill Lynch resumed coverage on Hershey (HSY) with an Underperform rating and $100 price target, as the firm expects shares to trade on fundamentals, which are under pressure. Last night, Mondelez (MDLZ) announced it has ended discussions with Hershey regarding a possible combination of the two companies. 2. eBay (EBAY) initiated with a Long-Term Buy at Hilliard Lyons by analyst Stephen Turner , who set a $35 price target on the stock. 3. Galapagos NV (GLPG) initiated with a Buy at Janney Capital by Debjit Chattopadhyay, who said that filgotinib, the company's oral JAK inhibitor, is "shaping up to be a blockbuster." 4. Gemphire Therapeutics (GEMP) initiated with with a Buy rating and $17 price target by Canaccord Genuity analyst John Newman and with a Buy rating and $15 price target by Jefferies analyst Matthew Andrews. 5. Sophiris Bio (SPHS) initiated with an an Overweight rating and $7 price target by Piper Jaffray analyst Charles Duncan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/30/16
JANY
08/30/16
INITIATION
Target $64
JANY
Buy
Galapagos NV initiated with a Buy at Janney Capital
Janney Capital analyst Debjit Chattopadhyay initiated Galapagos NV with a Buy rating and $64 fair value estimate, saying that filgotinib, the company's oral JAK inhibitor, is "shaping up to be a blockbuster," but noting as well that the company's Cystic Fibrosis program will dominate headlines over the next six to nine months.
06/16/16
LEER
06/16/16
NO CHANGE
Target $104
LEER
Outperform
Vertex remains ahead in cystic fibrosis, says Leerink
During their Annual R&D Update, Leerink analyst Geoffrey Porges says Galapagos (GLPG) presented the development plans for its cystic fibrosis franchise, in partnership with AbbVie (ABBV), which is a current threat to Vertex (VRTX). The announcement represents an "aggressive timeline" that would allow for a pivotal phase 3 for Galapagos' triple combination to begin in 2018 as a best case scenario, Porges tells investors in a research note. Nonetheless, the analyst believes Vertex's next generation combinations are much further along in development, with the company currently having a number of dual combination phase 3 trials underway. Porges reiterates an Outperform rating and $104 price target on Vertex's shares.
ABBV AbbVie
$61.82

-0.92 (-1.47%)

09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.

TODAY'S FREE FLY STORIES

TSN

Tyson Foods

$65.39

0.25 (0.38%)

17:05
04/24/17
04/24
17:05
04/24/17
17:05
Hot Stocks
Tyson Foods explores sale of three non-protein businesses »

As part of its strategic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

WHR

Whirlpool

$174.80

3.29 (1.92%)

17:05
04/24/17
04/24
17:05
04/24/17
17:05
Earnings
Whirlpool reports Q1 ongoing EPS $2.50, consensus $2.65 »

Reports Q revenue $4.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

IBTX

Independent Bank

$63.00

3.1 (5.18%)

17:05
04/24/17
04/24
17:05
04/24/17
17:05
Earnings
Independent Bank reports Q1 core EPS 84c, consensus 81c »

Net interest income was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CR

Crane

$77.91

1.37 (1.79%)

17:03
04/24/17
04/24
17:03
04/24/17
17:03
Earnings
Crane raises FY17 EPS view to $4.35-$4.55 from $4.30-$4.55, consensus $4.45 »

Max Mitchell, Crane Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

CR

Crane

$77.91

1.37 (1.79%)

17:02
04/24/17
04/24
17:02
04/24/17
17:02
Earnings
Crane reports Q1 EPS $1.05, consensus $1.00 »

Reports Q1 revenue $673M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

MRK

Merck

$62.14

0.25 (0.40%)

, BIIB

Biogen

$276.86

3.92 (1.44%)

17:02
04/24/17
04/24
17:02
04/24/17
17:02
Hot Stocks
FDA clears Remicade biosimilar from Samsung Bioepis »

The FDA has granted…

MRK

Merck

$62.14

0.25 (0.40%)

BIIB

Biogen

$276.86

3.92 (1.44%)

JNJ

Johnson & Johnson

$122.89

1.13 (0.93%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 31

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

AMP

Ameriprise

$131.86

3.42 (2.66%)

17:01
04/24/17
04/24
17:01
04/24/17
17:01
Hot Stocks
Breaking Hot Stocks news story on Ameriprise »

Ameriprise announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

AMP

Ameriprise

$131.86

3.42 (2.66%)

17:01
04/24/17
04/24
17:01
04/24/17
17:01
Hot Stocks
Breaking Hot Stocks news story on Ameriprise »

Ameriprise raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

AKRX

Akorn

$32.72

-0.19 (-0.58%)

, FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

17:00
04/24/17
04/24
17:00
04/24/17
17:00
Hot Stocks
Akorn backs FY17 adjusted EPS view $1.53-$1.72, consensus $1.63 »

Backs FY17 revenue view…

AKRX

Akorn

$32.72

-0.19 (-0.58%)

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMP

Ameriprise

$131.86

3.42 (2.66%)

17:00
04/24/17
04/24
17:00
04/24/17
17:00
Earnings
Ameriprise reports Q1 operating EPS $2.70, consensus $2.52 »

Reports Q1 revenue $2.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

SMMF

Summit Financial Group

$23.00

0.28 (1.23%)

17:00
04/24/17
04/24
17:00
04/24/17
17:00
Hot Stocks
Breaking Hot Stocks news story on Summit Financial Group »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

, AKRX

Akorn

$32.72

-0.19 (-0.58%)

16:59
04/24/17
04/24
16:59
04/24/17
16:59
Hot Stocks
Fresenius to acquire Akorn for $34 per share »

Fresenius Kabi (FSNUY)…

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

AKRX

Akorn

$32.72

-0.19 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

, AKRX

Akorn

$32.72

-0.19 (-0.58%)

16:58
04/24/17
04/24
16:58
04/24/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Fresenius SE, Akorn »

Fresenius to acquire…

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

AKRX

Akorn

$32.72

-0.19 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

, AKRX

Akorn

$32.72

-0.19 (-0.58%)

16:58
04/24/17
04/24
16:58
04/24/17
16:58
Periodicals
Breaking Periodicals news story on Fresenius SE, Akorn »

Fresenius SE to acquire…

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

AKRX

Akorn

$32.72

-0.19 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$53.65

0.65 (1.23%)

16:56
04/24/17
04/24
16:56
04/24/17
16:56
Hot Stocks
Wells Fargo: 'Pleased' with Fed, FDIC findings, committed to 'sound resolution' »

Wells Fargo issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

OMED

OncoMed

$3.77

0.04 (1.07%)

16:48
04/24/17
04/24
16:48
04/24/17
16:48
Hot Stocks
OncoMed announces workforce reduction »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ESRX

Express Scripts

$67.25

0.79 (1.19%)

, ANTM

Anthem

$168.41

0.61 (0.36%)

16:46
04/24/17
04/24
16:46
04/24/17
16:46
Hot Stocks
Express Scripts down 12% after contract with Anthem unlikely to be renewed »

In after hours trading,…

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 18

    May

  • 06

    Jun

OI

Owens-Illinois

$21.34

0.83 (4.05%)

16:46
04/24/17
04/24
16:46
04/24/17
16:46
Earnings
Owens-Illinois sees FY17 EPS $2.40-$2.50, consensus $2.43 »

The Company continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ESRX

Express Scripts

$67.25

0.79 (1.19%)

16:45
04/24/17
04/24
16:45
04/24/17
16:45
Hot Stocks
Breaking Hot Stocks news story on Express Scripts »

Express Scripts trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    Jun

OI

Owens-Illinois

$21.34

0.83 (4.05%)

16:44
04/24/17
04/24
16:44
04/24/17
16:44
Earnings
Owens-Illinois reports Q1 EPS 58c, consensus 53c »

Reports Q1 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WFC

Wells Fargo

$53.65

0.65 (1.23%)

16:44
04/24/17
04/24
16:44
04/24/17
16:44
Hot Stocks
Federal Reserve, FDIC approve revised Wells Fargo living will »

The Federal Deposit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

ESRX

Express Scripts

$67.25

0.79 (1.19%)

, ANTM

Anthem

$168.41

0.61 (0.36%)

16:43
04/24/17
04/24
16:43
04/24/17
16:43
Hot Stocks
Express Scripts CEO: 'Perplexed' by potential loss of Anthem contract »

Says Anthem deal is…

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 18

    May

  • 06

    Jun

SMMF

Summit Financial Group

$23.00

0.28 (1.23%)

16:41
04/24/17
04/24
16:41
04/24/17
16:41
Hot Stocks
Summit Financial Group announces resolution of litigation »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$80.05

0.77 (0.97%)

, ESRX

Express Scripts

$67.25

0.79 (1.19%)

16:39
04/24/17
04/24
16:39
04/24/17
16:39
Hot Stocks
Breaking Hot Stocks news story on CVS Health, Express Scripts, Anthem »

CVS up 2% after Express…

CVS

CVS Health

$80.05

0.77 (0.97%)

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 02

    May

  • 10

    May

  • 18

    May

  • 06

    Jun

NVS

Novartis

$74.61

1.21 (1.65%)

16:39
04/24/17
04/24
16:39
04/24/17
16:39
Hot Stocks
Novartis expands pact with Amgen to commercialize AMG 334 for migraine »

Novartis (NVS) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.